H.C. Wainwright analyst Yi Chen reiterated a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $34.00.
Yi Chen has given his Buy rating due to a combination of factors related to the promising developments in RegenXBio’s RGX-202 program for Duchenne muscular dystrophy (DMD). The recent presentation of positive interim data from the AFFINITY DUCHENNE trial showed consistent and strong microdystrophin expression in patients across various age groups. This expression level is significantly higher than the regulatory approval threshold, suggesting a favorable outlook for future trial results and potential accelerated approval.
Moreover, RGX-202 has demonstrated a favorable safety profile, with no serious adverse events reported. The trial’s ongoing success, including the enrollment of ambulatory patients and the anticipation of a Biologics License Application submission in mid-2026, further supports the Buy rating. These factors combined indicate a strong potential for RGX-202 to make a significant impact in the treatment of DMD, justifying the optimistic outlook on RegenXBio’s stock.
In another report released yesterday, Robert W. Baird also reiterated a Buy rating on the stock with a $39.00 price target.